LONDON, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage...
Emerging clinical data confirms the potential for RPL554 to be an important, novel treatment for patients with COPD LONDON, Nov. 07, 2017 (GLOBE...
LONDON, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage...
LONDON, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical...
October 2, 2017, LONDON - Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), in conformity with DTR 5.6 of the FCA's...
News) - NADSAQ and AIM-listed Verona Pharma PLC on Wednesday reported top-line results from its trial of RPL554 in chr ...
Earlier than expected results demonstrate absorption occurs primarily in the lungs following inhaled administration LONDON, Sept. 27, 2017...
LONDON, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a...
Issue of Shares September 19, 2017, London - Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage...
News) - Verona Pharma PLC on Thursday reported positive top-line results from its phase IIa clinical trial of RPL554 i ...
Achieved significant and clinically meaningful additional improvement in peak lung function and faster onset-of-action when added to tiotropium...
Achieved significant and clinically meaningful additional improvement in peak lung function and faster...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.